Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2026-03-13 00:00:00 ET · period of report 2026-03-12 · accession 0001193125-26-106724 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-03-13 | 2026-03-12 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | — | +12.5K | 27.2K | +85% | — |
| DT | 2026-03-13 | 2026-03-13 | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $55.23 | -7,308 | 19.9K | -27% | -$403.6K |
| DT | 2026-03-13 | 2026-03-12 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $0.00 | -12.5K | 37.5K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-03-12 | M | A | 12,500 | — | 27,231 | D | — | — | (F1) Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. |
| 2 | Common | Common Shares | 2026-03-13 | S | D | 7,308 | $55.23 | 19,923 | D | — | — | |
| 3 | Derivative | Restricted Share Units | 2026-03-12 | M | D | 12,500 | $0.00 | 37,500 | D | — · — to — | 12,500 Common Shares | (F1) Represents shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on March 12, 2025. The RSU award vests 25% on each of the first four anniversaries of the date of grant, beginning on March 12, 2026. |